Complete absence of M2-pyruvate kinase expression in benign pancreatic ductal epithelium and pancreaticobiliary and duodenal neoplasia

BMC Cancer

Volumn 9, Issue , 2009, Pages 327-

  Aloysius, Mark M ^a   Zaitoun, Abed M ^a   Bates, Timothy E ^b   Albasri, Abdulkader ^a   Ilyas, Mohammad ^a   Rowlands, Brian J ^a   Lobo, Dileep N ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PYRUVATE KINASE; PYRUVATE KINASE M2; UNCLASSIFIED DRUG;

ARTICLE; BILE DUCT CARCINOMA; CHRONIC PANCREATITIS; CONTROLLED STUDY; DUODENUM CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; PANCREAS RESECTION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TISSUE MICROARRAY;

AGED; CARCINOMA, PANCREATIC DUCTAL; DUODENAL NEOPLASMS; EPITHELIUM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; PANCREAS; PANCREATIC NEOPLASMS; PYRUVATE KINASE;

EID: 70349847268     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-327     Document Type: Article

References (28)

1. Eigenbrodt E, Basenau D, Holthusen S, Mazurek S, Fischer G. Quantification of tumor type M2 pyruvate kinase (Tu M2-PK) in human carcinomas. Anticancer Res 1997, 17:3153-3156.
2. Eigenbrodt E, Kallinowski F, Ott M, Mazurek S, Vaupel P. Pyruvate kinase and the interaction of amino acid and carbohydrate metabolism in solid tumors. Anticancer Res 1998, 18:3267-3274.
3. Schneider J, Morr H, Velcovsky HG, Weisse G, Eigenbrodt E. Quantitative detection of tumor M2-pyruvate kinase in plasma of patients with lung cancer in comparison to other lung diseases. Cancer Detect Prev 2000, 24:531-535.
4. Mazurek S, Zwerschke W, Jansen-Durr P, Eigenbrodt E. Metabolic cooperation between different oncogenes during cell transformation: interaction between activated ras and HPV-16 E7. Oncogene 2001, 20:6891-6898. 10.1038/sj.onc.1204792, 11687968.
5. Mazurek S, Boschek CB, Eigenbrodt E. The role of phosphometabolites in cell proliferation, energy metabolism, and tumor therapy. J Bioenerg Biomembr 1997, 29:315-330. 10.1023/A:1022490512705, 9387092.
6. Mazurek S, Eigenbrodt E. The tumor metabolome. Anticancer Res 2003, 23:1149-1154.
7. Brinck U, Eigenbrodt E, Oehmke M, Mazurek S, Fischer G. L- and M2-pyruvate kinase expression in renal cell carcinomas and their metastases. Virch Archiv 1994, 424:177-185.
8. Hardt PD, Toepler M, Ngoumou B, Rupp J, Kloer HU. Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls. Anticancer Res 2003, 23:851-853.
9. Schulze G. The tumor marker tumor M2-PK: an application in the diagnosis of gastrointestinal cancer. Anticancer Res 2000, 20:4961-4964.
10. Goonetilleke KS, Mason JM, Siriwardana P, King NK, France MW, Siriwardena AK. Diagnostic and prognostic value of plasma tumor M2 pyruvate kinase in periampullary cancer: evidence for a novel biological marker of adverse prognosis. Pancreas 2007, 34:318-324. 10.1097/MPA.0b013e31802ee9c7, 17414054.
11. Mottet N, Dumollard J-M, Gouzy-Grosjean F, Lucht-Versini P, Péoch M, Thibaudeau E, Rivière M. Expression profiling of M2PK in 19 different human tumor types. AACR Meeting Abstracts, April 2007 2007, 176. (accessed 1 June 2009)., http://www.aacrmeetingabstracts.org/cgi/content/meeting_abstract/2007/1_ Annual_Meeting/176?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=1 &author1=Mottet%2C+N&andorexacttitle=and&andorexacttitleabs= and&searchid=1&FIRSTINDEX=0&sortspec=relevance&fdate=1/1 /2004&tdate=12/31/2008&resourcetype=HWCIT
12. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998, 4:844-847. 10.1038/nm0798-844, 9662379.
13. Fons G, Hasibuan SM, Velden J, ten Kate FJ. Validation of tissue microarray technology in endometrioid cancer of the endometrium. J Clin Path 2007, 60:500-503. 10.1136/jcp.2006.040170, 16822874.
14. Richani K, Romero R, Kim YM, Cushenberry E, Soto E, Han YM, Espinoza J, Kim CJ. Tissue microarray: an effective high-throughput method to study the placenta for clinical and research purposes. J Matern Fetal Neonatal Med 2006, 19:509-515. 10.1080/14767050600852718, 16966117.
15. Friedrichs K, Gluba S, Eidtmann H, Jonat W. Overexpression of p53 and prognosis in breast cancer. Cancer 1993, 72:3641-3647. 10.1002/1097-0142(19931215)72:12<3641::AID-CNCR2820721215>3.0.CO;2-8, 8252480.
16. Oremek GM, Sapoutzis N, Kramer W, Bickeboller R, Jonas D. Value of tumor M2 (Tu M2-PK) in patients with renal carcinoma. Anticancer Res 2000, 20:5095-5098.
17. Oremek GM, Eigenbrodt E, Radle J, Zeuzem S, Seiffert UB. Value of the serum levels of the tumor marker TUM2-PK in pancreatic cancer. Anticancer Res 1997, 17:3031-3033.
18. Kim C-W, Kim JI, Park S-H, Han J-Y, Kim JK, Chung KW, Sun HS. Usefulness of plasma tumor M2-pyruvate kinase in the diagnosis of gastrointestinal cancer. Korean J Gastroenterol 2003, 42:387-393.
19. Roigas J, Deger S, Schroeder J, Wille A, Turk I, Brux B, Jung K, Schnorr D, Loening SA. Tumor type M2 pyruvate kinase expression in metastatic renal cell carcinoma. Urol Res 2003, 31:358-362. 10.1007/s00240-003-0331-4, 14513300.
20. Zhang B, Chen J-Y, Chen D-D, Wang G-B, Shen P. Tumor type M2 pyruvate kinase expression in gastric cancer, colorectal cancer and controls. World J Gastroenterol 2004, 10:1643-1646.
21. Luftner D, Mesterharm J, Akrivakis C, Geppert R, Petrides PE, Wernecke KD, Possinger K. Tumor type M2 pyruvate kinase expression in advanced breast cancer. Anticancer Res 2000, 20:5077-5082.
22. Hardt PD, Ngoumou BK, Rupp J, Schnell-Kretschmer H, Kloer HU. Tumor M2-pyruvate kinase: a promising tumor marker in the diagnosis of gastro-intestinal cancer. Anticancer Res 2000, 20:4965-4968.
23. Schneider J, Neu K, Velcovsky H-G, Morr H, Eigenbrodt E. Tumor M2-pyruvate kinase in the follow-up of inoperable lung cancer patients: a pilot study. Cancer Lett 2003, 193:91-98. 10.1016/S0304-3835(02)00720-6, 12691828.
24. Cerwenka H, Aigner R, Bacher H, Werkgartner G, el-Shabrawi A, Quehenberger F, Mischinger HJ. TUM2-PK (pyruvate kinase type tumor M2), CA19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions. Anticancer Res 1999, 19:849-851.
25. Christofk HR, Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL, Cantley LC. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008, 452:230-233. 10.1038/nature06734, 18337823.
26. Bergroth V, Reitamo S, Konttinen YT, E T. Fixation-dependent cytoplasmic false-positive staining with an immunoperoxidase method. Histochem Cell Biol 1982, 73:509-513.
27. Staib P, Hoffmann M, Schinkothe T. Plasma levels of tumor M2-pyruvate kinase should not be used as a tumor marker for hematological malignancies and solid tumors. Clin Chem Lab Med 2006, 44:28-31. 10.1515/CCLM.2006.006, 16375581.
28. Oremek GM, Gerstmeier F, Sauer-Eppel H, Sapoutzis N, Wechsel HW. Pre-analytical problems in the measurement of tumor type pyruvate kinase (tumor M2-PK). Anticancer Res 2003, 23:1127-1130.